Nanovaccinology as Targeted Therapeutics. Группа авторов

J., Dupuis, L., Ganne, V., Adjuvants designed for veterinary and human vaccines. Vaccine, 19, 2666–2672, 2001.

      101. Shah, P., Bhalodia, D., Shelat, P., Nanoemulsion: A pharmaceutical review. Sys. Rev. Pharm. 1, 24–32, 2010.

      102. Peek, L.J., Middaugh, C.R., Berkland, C., Nanotechnology in vaccine delivery. Adv. Drug Delivery Rev., 60, 915–928, 2008.

      103. O’Hagan, D.T., MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines, 6, 699–710, 2007.

      104. De Donato, S. et al., Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine, 17, 3094–3101, 1999.

      105. Nicholson, K.G. et al., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet (London, England), 357, 1937–1943, 2001.

106. Kumar, S. et al., CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun., 72, 949–957, 2004.

      107. Oliveira, G.A. et al., Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun., 73, 3587–3597, 2005.

      108. Dar, P. et al., Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. Vaccine, 31, 3327–3332, 2013.

      109. Zeng, B.J. et al., Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly. Small (Weinheim an der Bergstrasse, Germany), 9, 3736–3742, 2013.

      110. Kumar, S., Khilnani, G.C., Banga, A., Sharma, S.K., Predictors of requirement of mechanical ventilation in patients with chronic obstructive pulmonary disease with acute respiratory failure. Lung India: Off. Organ Indian Chest Soc., 30, 178–182, 2013.

      111. Nho, R., Pathological effects of nano-sized particles on the respiratory system. Nanomed.: Nanotechnol. Biol. Med., 29, 102242, 2020.

      112. Zhu, M. et al., Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc. Chem. Res., 46, 622–631, 2013.

      113. Yu, L.E. et al., Translocation and effects of gold nanoparticles after inhalation exposure in rats. Nanotoxicology, 1, 235–242, 2007.

      114. Gupta, I., Duran, N., Rai, M., Nano-antimicrobials, pp. 525–548, Springer, Berlin, Germany, 2012.

      115. Arms, L. et al., Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles. Front. Pharmacol., 9, 802, 2018.

      116. Sahdev, P., Ochyl, L.J., Moon, J.J., Biomaterials for nanoparticle vaccine delivery systems. Pharm. Res., 31, 2563–2582, 2014.

      1 *Corresponding author: [email protected]